Harmony Biosciences acquires Epygenix Therapeutics, Inc. to expand rare epilepsy franchise
Acquiring Company
Harmony Biosciences
Acquired Company
Epygenix Therapeutics
Plymouth MeetingParamusBiotechnologyHealth CareMedicalTherapeuticsBiopharmaBiotechnologyHealth CareTherapeuticsBiopharmaDescription
Harmony Biosciences has announced the acquisition of Epygenix Therapeutics, Inc., adding a late-stage epilepsy franchise to its growing pipeline of innovative CNS assets. With the acquisition, Harmony Biosciences aims to leverage its expertise and synergies to accelerate the development and commercialization of potential therapies for rare epilepsy conditions, emphasizing its commitment to addressing unmet medical needs in the neurological disorder space.
Quick answer
Harmony Biosciences is acquiring Epygenix Therapeutics, announced April 30, 2024. Harmony Biosciences is based in Plymouth Meeting, Pennsylvania, United States.
- How much did Harmony Biosciences pay for Epygenix Therapeutics?
- The deal value was not disclosed.
- What does Harmony Biosciences do?
- At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook.
- Where are Harmony Biosciences and Epygenix Therapeutics based?
- Harmony Biosciences is based in Plymouth Meeting, Pennsylvania, United States. Epygenix Therapeutics is based in Paramus, New Jersey, United States.
- Who are the decision-makers at Harmony Biosciences?
- Fundz holds 1 contact at Harmony Biosciences. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Medical and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Bristol Myers Squibb completes acquisition of Karuna Therapeutics, Inc. to strengthen its neuroscience portfolio (March 18, 2024)
- AbbVie finalizes acquisition of Landos Biopharma, Inc. to advance treatment for ulcerative colitis and Crohn's disease (May 23, 2024)
- Nuvation Bio Inc. completes acquisition of AnHeart Therapeutics Ltd. to enhance its oncology pipeline (April 10, 2024)
- Johnson & Johnson (J&J) completes $12.5 Billion Acquisition of Shockwave Medical to Strengthen Cardiac Health Solutions, $13B (April 5, 2024)
- Juvisé Pharmaceuticals acquires rights to MS therapy Ponvory outside North America (April 2, 2024)
- Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction (March 25, 2024)
Who to call at Harmony Biosciences, and when
When Harmony Biosciences changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Harmony Biosciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Harmony Biosciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Harmony Biosciences. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Harmony Biosciences makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Epygenix Therapeutics?
Epygenix Therapeutics was acquired by Harmony Biosciences, based in Plymouth Meeting. The deal was reported on April 30, 2024. At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. Harmony Biosciences is publicly traded (HRMY) and operates in Biotechnology.
When did Harmony Biosciences acquire Epygenix Therapeutics?
Harmony Biosciences's acquisition of Epygenix Therapeutics was reported on April 30, 2024. Harmony Biosciences has announced the acquisition of Epygenix Therapeutics, Inc., adding a late-stage epilepsy franchise to its growing pipeline of innovative CNS assets. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Epygenix Therapeutics do?
Epygenix Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for rare epilepsy conditions such as Dravet syndrome and Lennox-Gastaut syndrome. It is privately held, operating in Biotechnology, and is based in Paramus.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.